7/24/2014 - 9:45 AM EST - Pediapharm Inc. : announced today that a Special Access Program' from Health Canada has been initiated for Naproxen suspension. This program allows physicians to prescribe the product to their patients when no commercially available alternatives are available. This program has been initiated at the request of physicians mainly treating patients suffering of Juvenile Rheumatoid Arthritis. Pediapharm Inc.
shares V.PDP are trading down $0.02 at $0.28.
